183 related articles for article (PubMed ID: 31606550)
21. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations.
Riccioni R; Pelosi E; Riti V; Castelli G; Lo-Coco F; Testa U
Br J Haematol; 2011 Apr; 153(1):33-42. PubMed ID: 21332708
[TBL] [Abstract][Full Text] [Related]
22. Penfluridol triggers cytoprotective autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses.
Wu SY; Wen YC; Ku CC; Yang YC; Chow JM; Yang SF; Lee WJ; Chien MH
J Biomed Sci; 2019 Aug; 26(1):63. PubMed ID: 31470848
[TBL] [Abstract][Full Text] [Related]
23. The role of SRC family kinases in FLT3 signaling.
Kazi JU; Rönnstrand L
Int J Biochem Cell Biol; 2019 Feb; 107():32-37. PubMed ID: 30552988
[TBL] [Abstract][Full Text] [Related]
24. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
25. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
26. Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22
Moloney JN; Stanicka J; Cotter TG
Leuk Res; 2017 Jan; 52():34-42. PubMed ID: 27870947
[TBL] [Abstract][Full Text] [Related]
27. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
28. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
29. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
Agrawal S; Koschmieder S; Bäumer N; Reddy NG; Berdel WE; Müller-Tidow C; Serve H
Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
[TBL] [Abstract][Full Text] [Related]
30. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification.
Tian T; Li J; Li Y; Lu YX; Tang YL; Wang H; Zheng F; Shi D; Long Q; Chen M; Garcia-Manero G; Hu Y; Qin L; Deng W
Theranostics; 2019; 9(13):3768-3779. PubMed ID: 31281512
[TBL] [Abstract][Full Text] [Related]
31. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
32. Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling.
Moharram SA; Chougule RA; Su X; Li T; Sun J; Zhao H; Rönnstrand L; Kazi JU
Oncotarget; 2016 Sep; 7(36):57770-57782. PubMed ID: 27458164
[TBL] [Abstract][Full Text] [Related]
33. FLT3-driven redox-modulation of Ezrin regulates leukaemic cell migration.
Corcoran A; Cotter TG
Free Radic Res; 2013 Jan; 47(1):20-34. PubMed ID: 23009217
[TBL] [Abstract][Full Text] [Related]
34. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
Zhang X; Li B; Yu J; Dahlström J; Tran AN; Björkholm M; Xu D
Ann Hematol; 2018 Jan; 97(1):63-72. PubMed ID: 29080039
[TBL] [Abstract][Full Text] [Related]
35. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
Langdon WY
Crit Rev Oncog; 2012; 17(2):199-209. PubMed ID: 22471708
[TBL] [Abstract][Full Text] [Related]
36. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
[TBL] [Abstract][Full Text] [Related]
37. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
38. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
39. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
40. Signal transduction of oncogenic Flt3.
Choudhary C; Müller-Tidow C; Berdel WE; Serve H
Int J Hematol; 2005 Aug; 82(2):93-9. PubMed ID: 16146838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]